Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
175.90
-1.30 (-0.73%)
Sep 18, 2025, 11:36 AM EDT - Market open
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $23.74B in the quarter ending June 29, 2025, with 5.77% growth. This brings the company's revenue in the last twelve months to $90.63B, up 4.68% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$90.63B
Revenue Growth
+4.68%
P/S Ratio
4.71
Revenue / Employee
$656,242
Employees
138,100
Market Cap
423.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
| Thermo Fisher Scientific | 43.21B |
JNJ News
- 1 day ago - J&J's experimental psoriasis drug shows promise against Bristol's treatment - Reuters
- 1 day ago - Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis - PRNewsWire
- 3 days ago - Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting - PRNewsWire
- 5 days ago - COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says - Market Watch
- 6 days ago - J&J Painting Recognized with 2026 Consumer Choice Award for Painting Contractor in Waterloo - Accesswire
- 7 days ago - Johnson & Johnson seeks first European Medicines Agency approval for icotrokinra aiming to transform the plaque psoriasis treatment paradigm - GlobeNewsWire
- 7 days ago - Johnson & Johnson (JNJ) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 7 days ago - Trump's Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales. - Barrons